Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug Recognition.
Gajiwala, K.S., Feng, J., Ferre, R., Ryan, K., Brodsky, O., Weinrich, S., Kath, J.C., Stewart, A.(2013) Structure 21: 209-219
- PubMed: 23273428 
- DOI: 10.1016/j.str.2012.11.014
- Primary Citation of Related Structures:  
4I1Z, 4I20, 4I21, 4I22, 4I23, 4I24 - PubMed Abstract: 
The oncogenicity of the L858R mutant form of the epidermal growth factor receptor (EGFR) in non-small-cell lung cancer is thought to be due to the constitutive activation of its kinase domain. The selectivity of the marketed drugs gefitinib and erlotinib for L858R mutant is attributed to their specific recognition of the active kinase and to weaker ATP binding by L858R EGFR ...